{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:56:26Z","timestamp":1790682986306,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.clon.2008.07.002","type":"journal-article","created":{"date-parts":[[2008,8,30]],"date-time":"2008-08-30T07:04:36Z","timestamp":1220079876000},"page":"577-581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer \u2014 A Multi-Arm Multi-Stage Randomised Controlled Trial"],"prefix":"10.1016","volume":"20","author":[{"given":"N.D.","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.","family":"Dearnaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Popert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Stansfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.clon.2008.07.002_bib1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clon.2008.07.002_bib2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clon.2008.07.002_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clon.2008.07.002_bib4","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/1078-0432.CCR-07-0944","article-title":"Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study","volume":"14","author":"Berthold","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clon.2008.07.002_bib5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1464-410x.2000.00894.x","article-title":"Adjuvant mitozantrone chemotherapy in advanced prostate cancer","volume":"86","author":"Wang","year":"2000","journal-title":"BJU Int"},{"issue":"Suppl 3","key":"10.1016\/j.clon.2008.07.002_bib6","first-page":"81","article-title":"Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer","volume":"32","author":"Pummer","year":"1997","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.clon.2008.07.002_bib7","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.clon.2008.07.002_bib8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jnci\/djk178","article-title":"Oral sodium clodronate for nonmetastatic prostate cancer\u2013results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)","volume":"99","author":"Mason","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.clon.2008.07.002_bib9","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.clon.2008.07.002_bib10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2008.07.002_bib11","unstructured":"Prostate cancer: diagnosis and treatment. In: Cancer NCCf, editor. National Collaborating Centre for Cancer (2nd Floor, Front Suite, Park House, Greyfriars Road, Cardiff, CF10 3AF) at Velindre NHS Trust, Cardiff, Wales; 2008."},{"key":"10.1016\/j.clon.2008.07.002_bib12","unstructured":"SMC Advice Zoledronic acid. In: Scotland N, editor. 2004."},{"issue":"11","key":"10.1016\/j.clon.2008.07.002_bib13","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.clon.2008.07.002_bib14","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.clon.2008.07.002_bib15","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.clon.2008.07.002_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T","article-title":"Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone","volume":"83","author":"Magnetto","year":"1999","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.clon.2008.07.002_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2004.04.022","article-title":"Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer","volume":"46","author":"Montague","year":"2004","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clon.2008.07.002_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/(SICI)1097-0215(19980812)77:4<511::AID-IJC6>3.0.CO;2-X","article-title":"Non-steroidal anti-inflammatory drugs and prostate cancer progression","volume":"77","author":"Norrish","year":"1998","journal-title":"Inte J Cancer"},{"issue":"1","key":"10.1016\/j.clon.2008.07.002_bib19","first-page":"169","article-title":"Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study","volume":"7","author":"Nelson","year":"2000","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1016\/j.clon.2008.07.002_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4065\/77.3.219","article-title":"A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. [see comments.]","volume":"77","author":"Roberts","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.clon.2008.07.002_bib21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1470-2045(07)70280-2","article-title":"COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial","volume":"8","author":"Khor","year":"2007","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clon.2008.07.002_bib22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(07)70291-7","article-title":"Cyclooxygenase-2 inhibitors and prostate cancer","volume":"8","author":"James","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2008.07.002_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2407-6-15","article-title":"Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment","volume":"6","author":"Brubaker","year":"2006","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clon.2008.07.002_bib24","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1097\/00000421-200308002-00011","article-title":"Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines","volume":"26","author":"Witters","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clon.2008.07.002_bib25","doi-asserted-by":"crossref","unstructured":"Parmar MKB, Barthel FMS, Sydes MR, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst. doi: 10.1093\/jnci\/djn267.","DOI":"10.1093\/jnci\/djn267"},{"key":"10.1016\/j.clon.2008.07.002_bib26","series-title":"Am Soc Clin Oncol","author":"Bookman","year":"2006"},{"issue":"9582","key":"10.1016\/j.clon.2008.07.002_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","article-title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial","volume":"370","author":"Seymour","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clon.2008.07.002_bib28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198908173210702","article-title":"A controlled trial of leuprolide with and without flutamide in prostatic carcinoma","volume":"321","author":"Crawford","year":"1989","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clon.2008.07.002_bib29","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clon.2008.07.002_bib30","first-page":"613","article-title":"Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036","volume":"21","author":"Eisenberger","year":"1994","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2008.07.002_bib31","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1097\/01.ju.0000118294.88852.cd","article-title":"Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era","volume":"171","author":"Oefelein","year":"2004","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.clon.2008.07.002_bib32","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1464-410X.2005.05798.x","article-title":"A retrospective study of the time to clinical endpoints for advanced prostate cancer","volume":"96","author":"Sharifi","year":"2005","journal-title":"BJU Int"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655508003117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655508003117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:33:14Z","timestamp":1760542394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655508003117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0936655508003117"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2008.07.002","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer \u2014 A Multi-Arm Multi-Stage Randomised Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2008.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}